Traditional Chinese medicine–based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives - Scorecard - MDSpire

Traditional Chinese medicine–based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives

  • By

  • Hong Xu

  • Jingqing Hu

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Modulating Gut Microbiota in Coronary Heart Disease Through Traditional Chinese Medicine: Insights on Probiotic Interactions and Clinical Implications

At a Glance

CategoryDetail
Condition
Key MechanismsGut dysbiosis, microbiota-derived metabolites (TMAO, SCFAs), inflammation, cholesterol metabolism, endothelial injury, intestinal barrier integrity.
Target Population
Care Setting

Key Highlights

  • Gut microbiota is closely involved in the progression of CHD.
  • Phytomedicine modulates microbial metabolism, inflammation, and intestinal barrier function.
  • TMAO, SCFAs, and bile acid pathways link gut dysbiosis to CHD pathology.

Guideline-Based Recommendations

Diagnosis

  • Assess microbiota characteristics in patients with CHD.

Management

  • Consider phytomedicine and probiotics for microbiota modulation in CHD.

Monitoring & Follow-up

  • Monitor levels of microbiota-derived metabolites like TMAO and SCFAs.

Risks

  • Address potential long-term safety issues and standardization challenges in treatment.

Patient & Prescribing Data

Individuals diagnosed with Coronary Heart Disease.

Clinical Best Practices

    Related Resources & Content

    Original Source(s)

    Traditional Chinese medicine–based modulation of gut microbiota in coronary heart disease: probiotic synergy and translational perspectives

    • by Hong Xu, Jingqing Hu

    • June 2, 2026

    Related Content

    Establishment and validation of a machine learning-based predictive model for in-hospital mortality risk in acute myocardial infarction patients complicated with diabetes mellitus

    Identification and validation of STEAP3 as a ferroptosis-related biomarker in heart failure

    This Week’s CGT News: Base Editing Takes Aim at Cholesterol

    Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M

    • June 1, 2026

    • 5 min